Prognostic Significance of Frequent CLDN18-ARHGAP26/6 Fusion in Gastric Signet-Ring Cell Cancer.
Yang Shu,Weihan Zhang,Qianqian Hou,Linyong Zhao,Shouyue Zhang,Jiankang Zhou,Xiaohai Song,Yan Zhang,Dan Jiang,Xinzu Chen,Peiqi Wang,Xuyang Xia,Fei Liao,Dandan Yin,Xiaolong Chen,Xueyan Zhou,Duyu Zhang,Senlin Yin,Kun Yang,Jianping Liu,Leilei Fu,Lan Zhang,Yuelan Wang,Junlong Zhang,Yunfei An,Hua Cheng,Bin Zheng,Hongye Sun,Yinglan Zhao,Yongsheng Wang,Dan Xie,Liang Ouyang,Ping Wang,Wei Zhang,Meng Qiu,Xianghui Fu,Lunzhi Dai,Gu He,Hanshuo Yang,Wei Cheng,Li Yang,Bo Liu,Weimin Li,Biao Dong,Zongguang Zhou,Yuquan Wei,Yong Peng,Heng Xu,Jiankun Hu
DOI: https://doi.org/10.1038/s41467-018-04907-0
IF: 16.6
2018-01-01
Nature Communications
Abstract:Signet-ring cell carcinoma (SRCC) has specific epidemiology and oncogenesis in gastric cancer, however, with no systematical investigation for prognostic genomic features. Here we report a systematic investigation conducted in 1868 Chinese gastric cancer patients indicating that signet-ring cells content was related to multiple clinical characteristics and treatment outcomes. We thus perform whole-genome sequencing on 32 pairs of SRC samples, and identify frequent CLDN18-ARHGAP26/6 fusion (25%). With 797 additional patients for validation, prevalence of CLDN18-ARHGAP26/6 fusion is noticed to be associated with signet-ring cell content, age at diagnosis, female/male ratio, and TNM stage. Importantly, patients with CLDN18-ARHGAP26/6 fusion have worse survival outcomes, and get no benefit from oxaliplatin/fluoropyrimidines-based chemotherapy, which is consistent with the fact of chemo-drug resistance acquired in CLDN18-ARHGAP26 introduced cell lines. Overall, this study provides insights into the clinical and genomic features of SRCC, and highlights the importance of frequent CLDN18-ARHGAP26/6 fusions in chemotherapy response for SRCC.